PFE - Seagen gains amid options trades optimism for FTC approval for Pfizer deal
2023-12-05 16:48:42 ET
More on Seattle Genetics
- Seagen's Acquisition: EU Approval And Potential Upside
- FDA to decide on approving Keytruda/Padcev combo therapy by May 9
- Pfizer CFO reiterates Seagen closing expected later this year, early next year
- Seeking Alpha’s Quant Rating on Seattle Genetics
- Historical earnings data for Seattle Genetics
For further details see:
Seagen gains amid options trades, optimism for FTC approval for Pfizer deal